Padmashri Prof. I. Sathiyamurthy Discusses Hypotension in HFrEF - Importance and Management with Dr. D. Prabhakar

Prof. Peter Van Der Meer member of the working group of Peripartum Cardiomyopathy of ESC discusses Peripartum Cardiomyopathy- prevalence, caution, management and longterm data with Dr.D.Prabhakar at the HFAI 2026, Ahemedabad

Cardiac rehabilitation in Heart Failure.. explained by Dr.Dilip Kumar to Dr.D.Prabhakar at the HFAI 2026 at Ahemedabad

The National Heart Failure Registry one year aetiology wise outcomes are discussed by Dr. Harikrishnan with Dr. D. Prabhakar

Abraham Oomman discusses the heart failure with improved Ejection fraction.. the terminologies, the markers, the present and the future with Dr. D. Prabhakar

Curtain raiser for HFAI Annual Conference 2026 at Ahemedabad

WITHDRAW-AF trial discusses the withdrawal of GDMT in patients with AF and HFrEF that have improved their ejection fraction following restoration of sinus rhythm. Should GDMT be continued or can it be stopped and in whom ?

Read the full article

https://doi.org/10.1093/eurheartj/ehaf563

PARAGON- HF trial noted a BMI >=30 in 49% whereas Waist-Height ratio >= 0.5 was recorded in 96%.. BMI showed an obesity paradox while Waist height ratio did not.

Read the full article

https://doi.org/10.1093/eurheartj/ehaf057

Why do we need one ? The definition, Staging and Classification based on LV Ejection fraction.

Out with the old and In with the new terminologies

The basic definition of HFimpEF, and withdrawal of therapy here are discussed. The traditionally quoted trial is the TRED HF trial. A new trial called the CATHEDRAL trial using only carvedilol rather than complete withdrawal was similar to continuation of treatment. The clinical implications, and future of HFimpEF are discussed by Dr. Prabhakar Dorairaj.